Clinical Trial Update: Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating how microbiome metabolites and alcohol influence cardiovascular risk in people with HIV; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• HIV Infections

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Microtia, Dysbiosis | Phase 2 | Status: RECRUITING